PUBLISHER: Grand View Research | PRODUCT CODE: 1511893
PUBLISHER: Grand View Research | PRODUCT CODE: 1511893
The global brain imaging devices market size is anticipated to reach USD 9.04 billion by 2030, growing at a CAGR of 8.14% from 2024 to 2030. Key drivers propelling market growth include technological advancements, increasing R&D activities, and the growing prevalence of brain or neurological disorders. For instance, the International Agency for Research on Cancer reported approximately 321,731 cases of brain and central nervous system cancer worldwide in 2022. This type of cancer was noted to rank 19th among all other types of cancer.
Technological advancements are expected to be one of the primary factors contributing to market growth. These advancements encompass a spectrum of innovations, including enhanced imaging resolution, improved data processing capabilities, and the development of novel imaging modalities. Such progress not only enhances the accuracy and efficiency of brain imaging but also expands its applications across various fields such as neuroscience, neurology, psychiatry, and neurosurgery. For instance, in February 2024, Philips partnered with Synthetic MR, a company specializing in magnetic resonance imaging (MRI) software solutions, to introduce Smart Quant Neuro 3D, marking a notable advancement in providing objective decision support for the diagnosis and assessment of therapy effectiveness in brain disorders like multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. The Smart Quant Neuro 3D technology provides automated measurements of various brain tissues, aids in decision-making for brain diseases,
monitors disease progression, and assesses therapy results.
Additionally, the rising prevalence of neurological disorders and an aging population contribute to the increasing demand for advanced brain imaging technologies. With continuous research and development efforts driving innovation and the expansion of the market. Furthermore, various initiatives undertaken by market players are further expected to contribute to market growth. For instance, in November 2022, Neurosteer secured FDA approval for its single-channel electroencephalogram (EEG) brain monitoring platform. The company innovatively improved the conventional EEG system by incorporating an adhesive-backed electrode strip, seamlessly linking to a compact sensor, thus offering a more simplified and user-friendly solution.